Company Filing History:
1 out of 2,623 
1 out of 3,923 
Years Active: 2019
Title: The Remarkable Contributions of Inventor Joseph Fraietta
Introduction: Joseph Fraietta, an innovative inventor based in Cherry Hill, NJ, has made significant strides in the medical field, particularly in cancer treatment. With a focus on harnessing the power of Chimeric Antigen Receptor (CAR) technology, his work demonstrates the intersection of engineering and medicine in the fight against cancer.
Latest Patents: Fraietta holds a patent for the "Treatment of cancer using anti-CD19 Chimeric Antigen Receptor." This groundbreaking invention provides compositions and methods for treating diseases associated with CD19 expression. His approach involves administering a recombinant T cell that includes the CD19 CAR, often in combination with a kinase inhibitor. Additionally, his invention encompasses various kits and compositions aimed at enhancing treatment efficacy.
Career Highlights: Throughout his career, Joseph has collaborated with prominent institutions, including the University of Pennsylvania and Novartis AG. His work has not only contributed to academic advancements but has also paved the way for novel therapeutic strategies in oncology.
Collaborations: Collaborating with esteemed colleagues such as Carl H. June and David L. Porter, Fraietta has been at the forefront of research that integrates CAR technology and immunotherapy. These collaborations underscore the importance of teamwork in scientific discovery and patent innovation.
Conclusion: Joseph Fraietta exemplifies the innovative spirit that drives progress in healthcare. His patent on the treatment of cancer through anti-CD19 CAR demonstrates the potential of combining advanced genetic engineering with clinical applications. As he continues to explore new frontiers in medical research, his contributions will undoubtedly have a lasting impact on cancer treatment paradigms.